arrow
G

George Lau

humanity and health medical group
H指数:77
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Established vs. Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy

现有与新型策略用于乙型肝炎功能性治愈:聚乙二醇干扰素和贝皮洛韦森加用疗法的跨区域成本效益分析

2026-10-050
PRE
APASL clinical practice guidance: the diagnosis and management of patients with Wilson’s disease

APASL临床实践指南:Wilson’s disease患者的诊断与管理

2026-07-010
PREAI
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update

APASL关于慢性乙型肝炎感染管理的临床实践指南:2026年更新

2026-06-270
PREAI
Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure

糖尿病与酒精性慢性肝功能衰竭相关的更高死亡率相关联。

2025-10-250
PRE
Management of acute variceal bleeding: updated APASL guidelines

急性静脉曲张出血的管理:APASL指南更新

2025-08-310
PRE
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis

乙型肝炎病毒的新抗病毒疗法功能性治愈:一项系统评价和Meta分析

2025-06-180
OAAI
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新:曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

2025-04-110
OAAI
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

亚太研究协会《代谢功能障碍相关脂肪肝疾病诊断和管理的肝脏临床实践指南》

2025-02-270
PRE
Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia

急慢性肝衰竭(ACLF):来自亚洲的“京都共识”进展

2025-02-170
OAAI
Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Tremelimumab (T) 联合 Durvalumab (D) 治疗不可切除性肝细胞癌(uHCC)的III期HIMALAYA研究中,基于基线肝功能的5年总生存期(OS)和总生存期(OS)。

2024-12-011
PRE
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
2024-11-212
OA